Explore the exciting world of SGLT2 inhibitors with Dr. Harish Seethapathy, Dr. Matt Sparks, and Dr. Joel Topf. They discuss the mechanisms and benefits of these inhibitors for glucose control, cardiovascular health, and chronic kidney disease. The speakers delve into the hemodynamics and regulation of glomerular filtration and explore the various mechanisms of action of SGLT2 inhibitors, emphasizing their impact on inflammation, fibrosis, insulin sensitivity, and more. They also discuss the cancellation of Neffmatin and make predictions for the winners in the NephMadness 2020 SGLT2i region.
SGLT2 inhibitors have shown significant benefits in diabetes, heart failure, and kidney disease by reducing glucose reabsorption and sodium levels, leading to improved kidney function.
SGLT2 inhibitors have potential benefits in non-diabetic kidney disease, with studies suggesting improved kidney function and preservation of nephrons.
Deep dives
Summary of the podcast: SGLT2 inhibitors have shown significant benefits in diabetes, heart failure, and kidney disease. They work by reducing glucose reabsorption and sodium levels, leading to reduced intraglomerular pressure and improvement in kidney function. The drugs have also been found to have anti-inflammatory and fibrosis effects. While they can cause some side effects like mycotic infections and euglycemic decay, overall they have a good safety profile. Further studies are needed to explore their use in non-diabetic kidney disease and in kidney transplant patients.
SGLT2 inhibitors have shown significant benefits in diabetes, heart failure, and kidney disease. They work by reducing glucose reabsorption and sodium levels, leading to reduced intraglomerular pressure and improvement in kidney function. The drugs have also been found to have anti-inflammatory and fibrosis effects. Studies are ongoing to explore their use in non-diabetic kidney disease and in kidney transplant patients.
Potential benefits of SGLT2 inhibitors in non-diabetic kidney disease
SGLT2 inhibitors have potential benefits in non-diabetic kidney disease, with studies suggesting improved kidney function and preservation of nephrons. The drugs have shown to have anti-inflammatory and fibrosis effects, which can be beneficial in kidney disease. However, more research is needed to determine their full effectiveness and safety profile in this patient population.
Considerations for SGLT2 inhibitors in kidney transplant patients
There is limited data on the use of SGLT2 inhibitors in kidney transplant patients. While the drugs have shown benefits in diabetes and heart failure, concerns remain regarding osmotic diuresis, decreased GFR, and increased risk of mycotic infections. More studies are needed to understand the effectiveness and safety of these drugs in transplant patients.
Conclusion
SGLT2 inhibitors have emerged as promising drugs for diabetes, heart failure, and kidney disease. They have shown benefits in improving kidney function, reducing inflammation, and preserving nephrons. While further studies are needed, these drugs have the potential to significantly impact the treatment outcomes for various kidney-related conditions.
Get under the hood of SGLT2 inhibitors! Listen as our guests Dr. Harish Seethapathy, Dr. Matt Sparks, and Dr. Joel Topf give us a tour through the NephMadness 2020 SGLT2i region! How do these promising drugs work, and what evidence is there for using them in non-diabetic kidney disease or kidney transplant patients. Show Notes | Spotify | Swag! | Top Picks | Mailing List | thecurbsiders@gmail.com
Credits
Written and Produced by: Hannah R. Abrams
Cover Art and Infographic by: Hannah R. Abrams
Hosts: Hannah R Abrams, Matthew Watto MD, FACP
Editor: Clair Morgan of Nodderly.com (audio), Emi Okamoto MD (written)
Guests: Harish Seethapathy MD; Matthew Sparks MD; Joel Topf MD
Sponsor: McGraw Hill
Time Stamps
00:00 Sponsor
00:26 Intro, disclaimer, guest bio
02:57 Guest one-liner and Picks of the Week*: Michael Pollan audiobook on Coffee and Caffeine Addiction
03:52 SGLT2i definition, background, and why we now consider CV endpoints in diabetes
11:16 Sponsor
12:00 Tubuloglomerular feedback; Balloon analogy
17:40 Other mechanisms for SGLT2i
23:05 Back to the case; Risks from SGLT2i; Counseling and Monitoring
34:18 SGLT2i for non-diabetic kidney disease; Possible mechanisms: Joel’s caution against early adoption
41:42 SGLT2 inhibitors in kidney transplant
45:20 Take home points and picks for the SGLT2 inhibitor region
49:50 Outro
Get the Snipd podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share & Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode